Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Continuous Follow-Up: Our medical team monitors your response energy level, mental clarity, fatigue, and other changes after each session
Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding
The product is primarily formulated for adults
First published
K.SandersM
US$ 24.45
US$ 21.15
US$ 29.43
US$ 29.96
